
|Articles|March 1, 2004
Illuminating therapies
Washington, D.C. - Ongoing work regarding aminolevulinic acid (ALA) for photodynamic therapy provides a shining example of the value of off-label uses. The drug has earned UK approval for treating skin cancer and FDA approval for actinic keratoses. However, its most effective applications may well be cosmetic treatments including photo-rejuvenation, acne, and sebaceous gland hyperplasia.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
3
ICYMI: First Patient Dosed in Global Phase 2 Study of Oral TYK2 Inhibitor Soficitinib for PN
4
Dermatology Conferences and Meetings Calendar: December 2025
5


















